InnoCare Pharma Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Beijing, Beijing and currently employs 1,146 full-time employees. The company went IPO on 2020-03-23. InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The firm focuses on areas with unmet clinical needs, such as oncology and autoimmune diseases. The firm's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The firm is also developing products for the treatment of autoimmune diseases caused by abnormal T cell function. The firm conducts its businesses in domestic and overseas markets.
InnoCare Pharma Limited 주요 수익원은 Biopharmaceutical Research and Development, Manufacturing, Commercialization and Services이며, 최신 수익 발표에서 수익은 738,537,047입니다. 지역별로는 China이 InnoCare Pharma Limited의 주요 시장이며, 수익은 673,133,902입니다.
InnoCare Pharma Limited은 수익성이 있나요?
no, 최신 재무제표에 따르면 InnoCare Pharma Limited의 순손실은 $-440입니다.